Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Summary

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Detailed Description

PRIMARY OBJECTIVE: I. To evaluate immune profile of AML patients receiving venetoclax plus azacitidine induction chemotherapy. SECONDARY OBJECTIVE: I. To determine clinical responses based on immune infiltrated vs immune depleted subtypes of AML receiving azacitidine and venetoclax chemotherapy. OUTLINE: This is an observational study. Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.

Eligibility Criteria

Interventions